Fluorescent imaging agent - CEA-Leti/NICE ConsortiumAlternative Names: LipImage 815
Latest Information Update: 17 Jul 2013
At a glance
- Originator CEA-LETI
- Developer NICE Consortium
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer